Accelerating discovery: Transformative clinical trial models in neuro-oncology

Master protocol designs enable simultaneous evaluation of multiple therapies within shared, molecularly informed infrastructures, supporting precision medicine approaches and improving efficiency. Relative to traditional paradigms developed for systemic malignancies that typically test one agent at a time, this design places multiple therapies within a single molecularly stratified shared framework. A review-level conceptual framework presented descriptively, without specific trial counts or effect sizes.

Bayesian adaptive frameworks allow trials to learn during conduct, reallocating patients toward promising therapies and incorporating emerging biological data in real time. Whereas conventional phase II and III designs rely on assumptions fixed in advance, this framework builds learning during the trial and real-time biological data into the design itself. A design concept synthesized in the review, without specific statistical parameters or case data.

Trials can move beyond efficacy assessment to serve as active discovery platforms, embedding longitudinal tissue sampling, window-of-opportunity designs and multi-omic profiling to interrogate CNS drug penetrance, pharmacodynamic target engagement and treatment-induced tumor evolution directly in human disease. It expands trials from pure efficacy testing into discovery tools that also generate biological knowledge, responding to the limited tissue access characteristic of CNS tumors. A conceptual framework statement, without specific study results or sample sizes.

Decentralized trial models and artificial intelligence offer additional tools to broaden access, improve enrollment and reduce operational burden. Beyond traditional site-based trial models, it introduces decentralized conduct and AI tools as complementary means. Presented as potential tools in the review, described in general terms without quantitative evidence.

The framework is aimed at clinical trial designers, researchers and institutions working on central nervous system tumors, in settings that require molecular stratification, face limited tissue access and involve rapidly progressing disease; its value is in pointing toward trials as dynamic, biologically integrated, learning-based systems rather than providing directly applicable operational specifications.

Readers would still watch for the feasibility of these models in practice, their fit with regulatory and ethical frameworks, and the concrete effects of decentralized and artificial intelligence tools in CNS tumor populations; moreover, this reading is an overview text lacking figures and reference details, and whether those affect judgment of the framework's evidential strength remains an open question.